Citi Pharma Ltd.
PPSX:CPHL60.57
PKR
-0.90
(-1.46%)
ISIN
PK0126201018
Return %
Stock
S&P 500
1Y
-34.26
14.20
3Y
157.31
81.12
5Y
67.18
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Rizwan Ahmad
- Full Time Employees
- 633
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lahore Pakistan
- IPO Date
- Jul 9, 2021
- Website
- citipharma.com.pk
- Similar Companies
- Business
- Citi Pharma Limited is a Pakistan-based pharmaceutical company primarily engaged in the manufacturing, sale, and distribution of active pharmaceutical ingredients (APIs), finished dosage pharmaceutical formulations, and healthcare products. Founded in 2012 and headquartered in Lahore, Pakistan, the company operates through two core business segments: Active Pharmaceutical Ingredients (APIs) and Finished Formulations. Its API product portfolio includes bulk chemical synthesis and supply, featuring Paracetamol (Acetaminophen); Metformin Hydrochloride; Iron Choline Citrate; Diclofenac Sodium; Tramadol Hydrochloride; and Ciprofloxacin, serving major multinational and domestic pharmaceutical manufacturers. Its Finished Formulations segment develops, manufactures, and markets branded generic and generic pharmaceuticals across multiple delivery forms, including oral solid dosages such as tablets and capsules; liquid dosages including syrups and suspensions; dry powders; ointments; and sterile injectables. These products span diverse therapeutic categories, including analgesics and antipyretics; anti-infectives and antibiotics; cardiovascular treatments; anti-diabetics; gastrointestinal therapeutics; respiratory agents; and nutritional supplements. In addition, the company provides contract manufacturing, toll manufacturing, and private-label production services for institutional and commercial clients. Citi Pharma operates manufacturing facilities in the Punjab province and maintains distribution networks across Pakistan, alongside export operations targeting emerging markets in Central Asia, the Middle East, and Africa. In recent operational developments, Citi Pharma has executed major production capacity expansions across its API facilities, significantly increasing its dedicated Paracetamol production capacity from 3,600 metric tons to 6,000 metric tons per annum, as well as expanding formulation output capacities for solid and liquid dosages. The company has also entered into international technical collaborations, including a strategic alliance with Murli Krishna Pharma for advanced drug delivery systems, diversified into healthcare delivery through investments in a multi-specialty tertiary care hospital project in Lahore, and initiated registration pipelines to obtain international regulatory approvals for expanded export market penetration.